Presentations in this session:

10:20 WeOa0101    Abstract Powerpoint Clinical and biological factors at recruitment in HIV infected children in relation with three years survival in Abidjan, Côte d’Ivoire: the experience of the ANRS 1244/1278 study Msellati P.1, Anaky M.F.2, Rouet F.3, Kouakoussui A.2, Mercier S.4, Wemin M.L.5, N'Gbeche M.S.2, Fassinou P.6, Blanche S.7 1UMR 145 IRD, Bobo Dioulasso, Burkina Faso, 2Projet Enfant, PACCI, Abidjan, Côte d'Ivoire, 3Cedres, Abidjan, Côte d'Ivoire, 4UR 024, IRD, Montpellier, France, 5Pédiatrie, CHU Treichville, Abidjan, Côte d'Ivoire, 6Pédiatrie, CHU Yopougon, Abidjan, Côte d'Ivoire, 7Hopital Necker Enfants Malades, Paris, France

10:35 WeOa0102    Abstract Powerpoint Development of a paediatric HIV chronic care model to improve quality of care and accelerate the provision of antiretroviral therapy in Soweto, South Africa Moultrie H.1, Meyers T.2, Barker P.3 1School of Public Health, University of the Witwatersrand, Johannesburg, South Africa, 2Department of Paediatrics, University of the Witwatersrand, Johannesburg, South Africa, 3Department of Pediatrics, University of North Carolina, Chapel Hill, United States of America

10:50 WeOa0103    Abstract Powerpoint Early effectiveness of Triomune in HIV infected Ugandan children Barlow-Mosha L.1, Musoke P.2, Ajuna P.1, Luttajumwa M.1, Walabyeki J.1, Owor M.1, Mubiru M.1 1Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda, 2Makerere University - Johns Hopkins University Research Collaboration, Department of Pediatrics Makerere University, Kampala, Uganda

11:05 WeOa0104    Abstract Powerpoint Delayed complications of Bacillus Calmette- Guerin (BCG) vaccination in HIV infected children Fallo A.1, Torrado L.1, Sanchez A.1, Cerqueiro C.1, Shadgrosky L.1, Lopez E.L.1 1Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina

11:20 WeOa0105    Abstract Phenotypic and genotypic evidence for a delayed selection of thymidine-analogue mutations in children infected with subtype-C HIV-1 bearing the RT mutation M184V Engelhard D.1, Schapiro J.M.2, Averbuch D.1, Gradstein S.3, Gottesman G.4, Kedem E.5, Einhorn M.6, Grisaru-Soen G.7, Ofir M.8, Grossman Z.9 1Hadassah University Medical Center, Jerusalem, Israel, 2National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel, 3Kaplan Medical Center, Rehovot, Israel, 4Meir Medical Center, Kfar-Saba, Israel, 5Rambam Medical Center, Haifa, Israel, 6Soroka Medical Center, Beer Sheva, Israel, 7Sourasky Children's Medical Center, Tel-Aviv, Israel, 8Visible Genetics Inc., Kfar-Saba, Israel, 9National HIV Reference lab, Central Virology, PHL, MOH, Tel-Hashomer, Israel

11:35 WeOa0106    Abstract A randomised trial of resistance testing versus no resistance testing in children with virological failure: the PERA (PENTA 8) trial Giaquinto C.1, Green H.2, De Rossi A.3, Saidi Y.4, Compagnucci A.4, Girard S.4, Castelli-Gattinara G.5, Della Negra M.6, Pinto J.7, De Souza Marques H.H.8, Lyall E.G.H.9, Gibb D.M.2 1Department of Paediatrics, Padova, Italy, 2MRC Clinical Trials Unit, London, United Kingdom, 3Department of Oncology and Surgical Sciences, AIDS Reference Centre, Padova, Italy, 4INSERM SC10, Paris, France, 5Department of Infectious Diseases, Ospedale del Bambino Gesù, Rome, Italy, 6Instituto de Infectologia Emilio Ribas, São Paolo, Brazil, 7Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 8Hospital das Clinicas da Faculdade de Medicina USP, São Paolo, Brazil, 9St Mary's Hospital, London, United Kingdom